Target Cancer | The Young Adult Cancer Struggle: Fibrolamellar Carcinoma @TargetCancer | Uploaded August 2023 | Updated October 2024, 6 hours ago.
The Young Adult Cancer Struggle: Fibrolamellar Carcinoma | TARGET: Cancer Podcast | Ep. 47
In this informative video, Dr. Paul Kent sheds light on fibrolamellar carcinoma, a rare and often misdiagnosed liver cancer that mainly affects young adults. Understand the challenges faced by patients with fibrolamellar carcinoma and stay updated on recent successes in obtaining treatment approvals. Discover the DNAJB1-PRKACA mutation, treatment advancements, and the power of hope in facing this condition.
- - - -TimeStamps - - - -
00:00 Introduction
02:49 What is fibrolamellar carcinoma
06:36 Why fibrolamellar carcinoma is detected at advanced stage?
09:48 Molecular testings to detect fibrolamellar carcinoma
10:37 DNAJB1-PRKACA
16:45 Outcomes for AYA are worst today than before
22:38 Treating fibrolamellar carcinoma
30:45 Tumor boards
- - - -
#cancertreatment #fibrofighters #fibrolamellar #AYAcommunity #livercancer
🔴Like, Subscribe, and Share to see more of this type of content!
— ABOUT DR. PAUL KENT —
Dr. Kent has been a Pediatric Hematologist and Oncologist for 25 years, including 18 years at Rush as the Director for Physicianship, Role Leader for Advocacy, Creator of the Social Justice and Health Equity Leadership Track, and Founder of the Rush Fibrolamellar Carcinoma Program. Dr. Kent was educated at Harvard (BS), Mayo Clinic (MD), University of Chicago (Pediatrics) and then Northwestern Lurie Children’s Hospital (Pediatric Oncology) where his research interests included social medicine (unconscious bias in medicine, medical racism) as well as pediatric sarcomas, adolescent and young adult cancers and, of course, fibrolamellar carcinoma of the liver.
After retiring from Rush, Dr. Kent began consulting for the FibroFighters Foundation in order to dedicate all of his energy, research, and advocacy to this rare cancer. Dr. Kent has numerous research publications and national presentations on fibrolamellar carcinoma.
— ABOUT DR. SANJAY JUNEJA —
Dr. Sanjay Juneja is a triple board-certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, a social & news media personality known as the 'TheOncDoc' with over half a million followers, and one of fifteen social media doctors participating in the Healthcare Leaders in Social Media Round Table Series for the White House.
He has been featured by The Washington Post as well as dozens of national podcasts and regional news channels (PBS, CBS, NBC, NPR), and has given keynote speeches and partnered with American Cancer Society, BeTheMatch, Leukemia & Lymphoma Society, Harvard University, Louisiana Department of Health and several others.
— ABOUT xCURES —
The xCures platform is a direct-to-patient and direct-to-physician portal that identifies the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.
The platform captures data that also helps accelerate the development of promising new cancer drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement.
Learn more at: xcures.com
Facebook: facebook.com/xcures.platform
TikTok: tiktok.com/@xcures.platform
Instagram: instagram.com/xcures.platform
LinkedIn: linkedin.com/company/xcures
Twitter: twitter.com/xcures_platform
TARGET: Cancer Podcast
Homepage: xcures.com/target-cancer-podcast
YouTube: youtube.com/TargetCancer
Spotify: open.spotify.com/show/2xMG5y5gOoIut5Ykvm63XO?si=0b478259417f40f4
iTunes: podcasts.apple.com/us/podcast/target-cancer-podcast/id1593087681
TuneIn:
tunein.com/podcasts/Technology-Podcasts/Target-Cancer-Podcast-p1761270/?topicId=176003304
Google Podcasts:
podcasts.google.com/feed/aHR0cHM6Ly9mZWVkLnBvZGJlYW4uY29tL210cnVkbmFrL2ZlZWQueG1s
Pandora:
pandora.com/podcast/target-cancer-podcast/PC:1001022571
Amazon Music:
music.amazon.com/podcasts/a8011808-57b8-42b3-a6df-abe02bb9011d
The Young Adult Cancer Struggle: Fibrolamellar Carcinoma | TARGET: Cancer Podcast | Ep. 47
In this informative video, Dr. Paul Kent sheds light on fibrolamellar carcinoma, a rare and often misdiagnosed liver cancer that mainly affects young adults. Understand the challenges faced by patients with fibrolamellar carcinoma and stay updated on recent successes in obtaining treatment approvals. Discover the DNAJB1-PRKACA mutation, treatment advancements, and the power of hope in facing this condition.
- - - -TimeStamps - - - -
00:00 Introduction
02:49 What is fibrolamellar carcinoma
06:36 Why fibrolamellar carcinoma is detected at advanced stage?
09:48 Molecular testings to detect fibrolamellar carcinoma
10:37 DNAJB1-PRKACA
16:45 Outcomes for AYA are worst today than before
22:38 Treating fibrolamellar carcinoma
30:45 Tumor boards
- - - -
#cancertreatment #fibrofighters #fibrolamellar #AYAcommunity #livercancer
🔴Like, Subscribe, and Share to see more of this type of content!
— ABOUT DR. PAUL KENT —
Dr. Kent has been a Pediatric Hematologist and Oncologist for 25 years, including 18 years at Rush as the Director for Physicianship, Role Leader for Advocacy, Creator of the Social Justice and Health Equity Leadership Track, and Founder of the Rush Fibrolamellar Carcinoma Program. Dr. Kent was educated at Harvard (BS), Mayo Clinic (MD), University of Chicago (Pediatrics) and then Northwestern Lurie Children’s Hospital (Pediatric Oncology) where his research interests included social medicine (unconscious bias in medicine, medical racism) as well as pediatric sarcomas, adolescent and young adult cancers and, of course, fibrolamellar carcinoma of the liver.
After retiring from Rush, Dr. Kent began consulting for the FibroFighters Foundation in order to dedicate all of his energy, research, and advocacy to this rare cancer. Dr. Kent has numerous research publications and national presentations on fibrolamellar carcinoma.
— ABOUT DR. SANJAY JUNEJA —
Dr. Sanjay Juneja is a triple board-certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, a social & news media personality known as the 'TheOncDoc' with over half a million followers, and one of fifteen social media doctors participating in the Healthcare Leaders in Social Media Round Table Series for the White House.
He has been featured by The Washington Post as well as dozens of national podcasts and regional news channels (PBS, CBS, NBC, NPR), and has given keynote speeches and partnered with American Cancer Society, BeTheMatch, Leukemia & Lymphoma Society, Harvard University, Louisiana Department of Health and several others.
— ABOUT xCURES —
The xCures platform is a direct-to-patient and direct-to-physician portal that identifies the most promising treatment options for advanced cancer patients who are not responding to standard of care therapies.
The platform captures data that also helps accelerate the development of promising new cancer drugs, expand the approved uses of existing drugs, and demonstrate value for reimbursement.
Learn more at: xcures.com
Facebook: facebook.com/xcures.platform
TikTok: tiktok.com/@xcures.platform
Instagram: instagram.com/xcures.platform
LinkedIn: linkedin.com/company/xcures
Twitter: twitter.com/xcures_platform
TARGET: Cancer Podcast
Homepage: xcures.com/target-cancer-podcast
YouTube: youtube.com/TargetCancer
Spotify: open.spotify.com/show/2xMG5y5gOoIut5Ykvm63XO?si=0b478259417f40f4
iTunes: podcasts.apple.com/us/podcast/target-cancer-podcast/id1593087681
TuneIn:
tunein.com/podcasts/Technology-Podcasts/Target-Cancer-Podcast-p1761270/?topicId=176003304
Google Podcasts:
podcasts.google.com/feed/aHR0cHM6Ly9mZWVkLnBvZGJlYW4uY29tL210cnVkbmFrL2ZlZWQueG1s
Pandora:
pandora.com/podcast/target-cancer-podcast/PC:1001022571
Amazon Music:
music.amazon.com/podcasts/a8011808-57b8-42b3-a6df-abe02bb9011d
